the products. The company then filed a Writ Petition in the Delhi High Court. After the judgement of the Court they have now complied with the categorisation of the two products.

Lapses in the New drug policy

107. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to state:

(a) whether the attention of Government has been drawn to the Editorial under the caption "Drug Policy" appeared in Indian Express on 17th March, 1986;

(b) if so, whether it is a fact the Government have only consulted the drug industry in the formulation of policy and have totally ignored the suggestions made in the interest of the consumer;

(c) whether it is also a fact that the proposed policy is likely to prove a vital disappointment to the consumer;

(d) whether it is also a fact that the policy will be restricting only to pricing and production and ignoring other aspects such as quality of drugs, excessive irrational combination of drugs and marketing of useless and harmful medicines; and

(e) if so, what are the reasons for ignoring these aspects

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) to (d). The policy has not been finalized yet.

(e) Does not arise.

Prices of Medicines

108. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the prices of medicines are not fixed on the basis of actual purchase prices and actual landed cost of imports of bulk drugs;

(b) if so, why the actual purchase invoices and actual landed cost of imports of bulk drugs are not verified before fixation of formulation prices;

(c) whether it is also a fact that drug companies made huge unintended benefits with this procedure; and

(d) what steps are being taken to save the consumers from such procedure of fixation of high prices?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JALCHANDRA SINGH): (a) While fixing the prices of formulations, indigenous price as fixed by the Government, landed cost of import of individual importer weighted average import price or the actual cost of the purchase, whichever is lower is taken into consideration.

(b) to (d). The prices for the bulk drugs as fixed by the Government are maximum sale prices. The manufacturers of bulk drugs on account of competition or other reasons can sell the bulk drugs at prices not exceeding the notified prices. The international prices of imported bulk drugs also change from time to time on account of fluctuation in the exchange rate and or changes in the import prices. On account of such factors at times there could be a difference between the price of bulk drug allowed in the formulations and actual import/procurement price. As and when there are such substantial differences, steps are taken to revise prices.

Demand to increase equity shares by Suzuki Motors Ltd.

109. SHRI RAMCHANDRA BHARADWAJ: Will the Minister of INDUSTRY be pleased to state:

(a) whether the Suzuki Motors Ltd., the Japanese Collaborator of Maruti Udyog Ltd., has desired an increase in its equity shares in the latter;

(b) if so, what is their precise demand; and

(c) what is Govt.'s reaction thereto?

THE MINISTER OF STATE IN THE DEPARTMENT OF INDUSTRIAL DEVELOPMENT (SHRI M. ARUNACHALAM): (a) No, Sir.

(b) and (c). Do not arise.

Production of Bulk Drugs

110. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state:

(a) names of the bulk drugs which are partly imported and partly manufactured in the country;

(b) what is the estimated requirement of each drug for the period 1986-87;

(c) what is the total installed capacity of each drug in the country;

(d) whether it is a fact that these drugs are allowed for import under Open General Licence;

(e) if so, names of drugs under OGL;

(f) whether it is also a fact that indigenous producers can meet the total requirement of bulk drugs in the country;

(g) if so, what steps have been taken by Government to safeguard the interests of indigenous producers to produce upto the available installed capacity; and

(h) what is the present position in this direction?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) At present about 500 drugs are used in the country. About 225 of these are produced indigenously. The names of 347 bulk drugs are listed in the Drugs (Prices Control) Order, 1979.

(b) The estimated requirements of various bulk drugs as estimated by the Working Group on Drugs & Pharmaceuticals for the 7th Five Year Plan have been published in their report, copy of which is available in the Parliament Library.

(c) Details of industrial licences granted along with the capacity approved etc. are being published regularly by the India Investment Centre in their Monthly News Letter copies of which are available in the Parliament Library.

(d) and (e). The bulk drugs which are not specified in Appendix 2 (List of banned/restricted items), Appendix-3- Part A (List of Limited Permissible Items) or Appendix 5 (List of items import of which is allowed to canalising agency) are allowed for import under Open General Licence (OGL).

(f) to (h). The import policy of a drug is formulated in consideration of several factors including its domestic demand vis-a-vis indigenous production. The import of a drug is normally allowed to fill the gap between the demand and the indigenous production.

Licensed drug companies

111. SHRI RAFIQUE ALAM. Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that every drug company has to produce twenty per cent of the sales turnover of categories I and II of drugs;

(b) the names of drug companies who are licensed to produce bulk drugs and formulations falling under categories I and II;

(c) the production of each company during 1979-80 and what was the production during 1985-86;

(d) the percentage increase and decrease in each case; and

(e) the percentage increase or decrease in the total production of drugs and formulations from the year 1979-80 to 1985-86?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) There is no statutory binding to this effect. Paragraph 59 of the 1978 Drug Policy, however, provides that it will be ensured progressively that at least 20 per cent of the